Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC)

Next Previous
Trial Profile

A 3-Year, Multi-Center, Long-Term Safety (LTS) Study to Evaluate the Safety and Tolerability of TD-1473 in Subjects with Ulcerative Colitis (UC)

Status: Discontinued
Phase of Trial: Phase II/III

Latest Information Update: 14 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Izencitinib (Primary)
  • Indications Ulcerative colitis
  • Focus Adverse reactions; Registrational
  • Acronyms TD-1473 LTS UC
  • Sponsors Theravance Biopharma

Most Recent Events

  • 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
  • 16 Nov 2021 Status changed from active, no longer recruiting to discontinued.
  • 16 Oct 2021 This trial has been discontinued in Spain(End Date: 01 Sep 2021), according to European Clinical Trials Database record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top